Replies to post #20149 on Mymetics Corp (MYMX)

[Work Harder]

Screening, Malaria, Clinical Development

Microbiology @ Universität Bern

Discovery, Target Discovery, High Throughput

Screening, Malaria, Clinical Development,

https://rocketreach.co/shinji-okitsu-email_16467930

A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers

https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0001018

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142655080

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157426833

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157420669

https://www.cell.com/cell-chemical-biology/comments/S1074-5521(07)00146-9

https://www.researchgate.net/profile/Shinji_Okitsu

LOL

[siar]

Thank you very much!
I am still hoping for progress regarding birch pollen. That should be much closer to some money than the SARS-CoV-2 vaccine projects. Perhaps MYMX has also potential because of its cold chain independent delivery system - BioNTech's CEO said their vaccine is almost perfect, but they need cold storage. But that's only hopes. The birch pollen project is much further. If I take in account the number of press releases that cooperation with Anergis and Mymetics is not only one among many to Stallergenes Greer. I would like to know how successful the tests were - only a bit or really successful.

[Work Harder]

Plasmodium falciparum malaria AND Plasmodium falciparum malaria

https://www.unboundmedicine.com/medline/research/Plasmodium%20falciparum%20malaria/Plasmodium_falciparum_malaria

Ape Origins of Human Malaria

Just like Hiv

https://www.swisstph.ch/fr/publications/publication-action/list/publication-controller/Publications/publication-authors-0/34474/

https://www.nature.com/articles/s41541-020-0158-9

Scientists worried the pandemic would cause malaria deaths to soar. So far, it hasn’t happened

https://www.sciencemag.org/news/2020/08/scientists-worried-pandemic-would-cause-malaria-deaths-soar-so-far-it-hasnt-happened

[Work Harder]

The Wall Street Journal reported that Merck’s Covid-19 vaccine candidate will begin a Phase 1/2 trial to evaluate safety and whether or not the vaccine creates an immune response to the novel coronavirus. The study is looking to enroll 260 people in Belgium, and is projected to be completed in April, The Journal reported, citing clincicaltrials.gov—though that may prove conservative. Phase 3 data from competing vaccines to determine effectiveness are expected to begin rolling out this fall.

https://www.barrons.com/articles/news-updates-51599826515?mod=hp_LEAD_1_B_3

The phase 1/2 trial, which is based in Belgium, aims to recruit 260 healthy participants to test the experimental vaccine V591, which it gained access to as part of its May deal for Austrian vaccine maker Themis Bioscience.

https://www.reuters.com/article/health-coronavirus-merck-co/update-1-merck-starts-recruitment-for-covid-19-vaccine-trial-idUSL4N2G83QW

The vaccine is based on a modified measles virus that delivers bits of the new coronavirus into the body to prevent COVID-19.

The drugmaker is also collaborating with research non-profit IAVI on a second vaccine candidate that uses the same technology as Merck’s Ebola vaccine, ERVEBO.

Earlier this month, Chief Executive Kenneth Frazier had said the second candidate is likely to begin trials later this year.

[Work Harder]

Oh yeow, so the Baylor gal is speaking in China Nov 3

I assume virtually

Drop da bomb

Vaccine Congress Washington Agenda

LIVE, 28 SEPTEMBER 2020 - 1 OCTOBER 2020

Stanley Plotkin,

Emeritus Professor,University of Pennsylvania School Of Medicine

AF & more

https://www.terrapinn.com/conference/world-vaccine-congress-washington/agenda.stm

Dr Peter Hotez / Panel: What existing treatments and vaccine development platforms show promise to control the rate of infection and spread?

29 SEPTEMBER 2020

Themis Bioscience

30 SEPTEMBER 2020

Dr Peter Hotez / Global health challenges: Controlling treatable infectious diseases

George Buchman / Next-generation vaccines and oncolytic viruses: Current challenges and future promise

George Buchman, VP, Preclinical & Process Development,
Catalent Cell & Gene Therapy